HC Wainwright reaffirmed their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock.
A number of other equities analysts also recently commented on CAPR. Oppenheimer assumed coverage on Capricor Therapeutics in a research note on Friday, May 17th. They issued an outperform rating and a $14.00 price target for the company. LADENBURG THALM/SH SH lifted their target price on Capricor Therapeutics from $24.00 to $25.00 and gave the company a buy rating in a research note on Tuesday, May 14th. StockNews.com downgraded Capricor Therapeutics from a hold rating to a sell rating in a research note on Tuesday, May 14th. Finally, Cantor Fitzgerald restated an overweight rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, May 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $21.75.
Check Out Our Latest Research Report on Capricor Therapeutics
Capricor Therapeutics Stock Performance
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.20). The firm had revenue of $4.91 million during the quarter, compared to analyst estimates of $10.00 million. Capricor Therapeutics had a negative return on equity of 231.68% and a negative net margin of 89.72%. On average, equities research analysts forecast that Capricor Therapeutics will post -1.04 EPS for the current fiscal year.
Hedge Funds Weigh In On Capricor Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after buying an additional 200,499 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics during the first quarter worth approximately $40,000. Jump Financial LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth approximately $258,000. Finally, Citigroup Inc. acquired a new position in shares of Capricor Therapeutics during the third quarter worth approximately $211,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Articles
- Five stocks we like better than Capricor Therapeutics
- ESG Stocks, What Investors Should Know
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What is the Dogs of the Dow Strategy? Overview and Examples
- AbbVie Stock: A Perfect Dip for Investors to Buy
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.